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1  | INTRODUC TION
Cardiac resynchronization therapy (CRT) reduces heart failure 
symptoms and improves clinical outcomes in selected patients with 
broad QRS complex.1,2 This treatment has proven beneficial, with a 
reduction in the mortality and hospitalization rates when combined 
with medical therapy. However, a significant fraction of patients do 
not experience improvements in symptoms or cardiac function.3 A 
 
Received: 5 August 2020  |  Revised: 24 September 2020  |  Accepted: 19 October 2020
DOI: 10.1002/joa3.12450  
O R I G I N A L  A R T I C L E
Performance of an active fixation bipolar left ventricular 
lead vs passive fixation quadripolar leads in cardiac 
resynchronization therapy, a randomized trial
Havard Keilegavlen MD1,2  |   Peter Schuster MD, PhD1,2 |   Thomas Hovstad MD1 |   
Svein Faerestrand MD, PhD1,2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society
1Department of Heart Disease, Haukeland 
University Hospital, Bergen, Norway
2Department of Clinical Science, University 
of Bergen, Bergen, Norway
Correspondence
Havard Keilegavlen, Department of Heart 
Disease, Haukeland University Hospital, Pb 
1400, 5021 Bergen, Norway.
Email: havard.keilegavlen@gmail.com
Abstract
Background: Usage of active fixation bipolar left ventricular (LV) leads represents an 
alternative approach to the more commonly used passive fixation quadripolar leads 
in cardiac resynchronization therapy (CRT). We compared a bipolar LV lead with a 
side screw for active fixation and passive fixation quadripolar LV leads.
Methods: Sixty-two patients were before CRT implantations randomly allocated to 
receive a bipolar (n = 31) or quadripolar (n = 31) LV leads. Speckle-tracking radial 
strain echocardiography was used to define the LV segment with latest mechanical 
activation as the target LV segment. The electrophysiological measurements and the 
capability to obtain a proximal position in a coronary vein placed over the target seg-
ment were assessed.
Results: Upon implantation, the quadripolar lead demonstrated a lower pacing cap-
ture threshold than the bipolar lead, but at follow-up, there was no difference. There 
were no differences in the LV lead implant times or radiation doses. The success rate 
in reaching the target location was not significantly different between the two LV 
leads.
Conclusions: The pacing capture thresholds were low, with no significant difference 
between active fixation bipolar leads and quadripolar leads. Active fixation leads did 
not promote a more proximal location of the stimulating electrode or a higher grade 
of concordance to the target segment than passive fixation leads.
K E Y W O R D S
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nonoptimal position of the left ventricular (LV) lead is a major reason 
for an inferior response to CRT.4,5 Placement of the LV lead in a seg-
ment remote from the region with the latest mechanical activation 
or in a segment with a myocardial scar predicts a high risk for non-
response. Echocardiographic speckle-tracking two-dimensional (2D) 
radial strain imaging has the ability to identify the LV segment with 
the latest mechanical activation. LV lead implantation guided by this 
robust echocardiographic method has been shown to augment the 
clinical outcomes of CRT compared with those of unguided LV lead 
placement.6,7 The optimal location for LV pacing may be different 
from the best position for lead stability and may be compromised to 
achieve a stable lead position with a low risk of lead dislodgement. 
Available quadripolar LV leads provide multiple options of different 
pacing vector and are particularly useful for eliminating postopera-
tive phrenic nerve stimulation (PNS) by reprogramming lead config-
uration.8,9 Active fixation mechanisms of LV leads facilitate stable 
lead positions in a wide range of venous anatomies.10 The aim of the 
current study was to compare a bipolar LV lead with a side helix for 
active fixation and a quadripolar LV lead with passive fixation re-
garding the electrophysiological performance, the stability, and the 
ability to reach the target position.
2  | METHODS
2.1 | Study design
In this prospective, randomized, single-center trial, patients with 
symptomatic heart failure and an indication for CRT implantation in 
accordance with current guidelines were included. The study was 
approved by the regional committee for medical and health research 
ethics (Reference 2015/1507), and all patients gave their written in-
formed consent. The patients were blinded and randomly assigned 
to receive either an active fixation lead or a quadripolar passive fix-
ation lead. For patients randomized to receive a quadripolar lead, 
the operators were free to choose between three different shapes. 
Prior to randomization, the patients were stratified into two cohorts 
based on whether they received a CRT device either with a defibril-
lator (CRT-D) or without a defibrillator (CRT-P). The decision of im-
planting a CRT-D or a CRT-P was done individually based on etiology 
of the heart failure and the patient's comorbidity.
2.2 | Patient population
Between February 2016 and November 2017, 62 patients were in-
cluded and randomized. The inclusion criteria, which were based on 
current guidelines, were symptomatic heart failure; New York Heart 
Association (NYHA) functional class II or III or ambulant class IV; LV 
ejection fraction ≤35%; and left bundle branch block (LBBB) with a 
QRS duration ≥120 ms or non-LBBB with a QRS duration ≥150 ms The 
baseline clinical characteristics and comorbidities of the patients are 
described in Table 1. No significant differences were found between 
the two patient groups with respect to sex, QRS duration, LV ejection 
fraction, NYHA functional class, medication, and comorbidities. The 
average NYHA functional class was 2.7 in both patient groups.
2.3 | Echocardiographic imaging
The LV ejection fraction was measured by echocardiography using 
the biplane modified Simpson's method (GE Vivid E9, Vingmed 
Ultrasound, Horten, Norway). Transthoracic echocardiography 
with 2D speckle-tracking radial strain (ST-RS) measurements of the 
LV was performed prior to the implantation procedures. All images 
were processed offline (EchoPac 202 GE Medical System, Horten, 
Norway). Intraventricular LV dyssynchrony was determinated using 
ST-RS echocardiography from 2D images in a mid-LV parasternal 
short-axis view with a frame rate ≥50 Hz. Time-strain curves were 
computed for the different LV segments. Left ventricular segments 
with a strain rate <10% were excluded because this finding was 
considered to indicate a high level of transmural scarring.11,12 The 
time from Q-wave onset on the electrocardiogram to the maximal 
radial strain in the anterior, lateral, and posterior LV segments was 









Female sex, n (%) 11 (35) 6 (20) .18
Age, years 71.5 ± 13 72.2 ± 10 .82
Left ventricular 
ejection fraction, %
24.4 ± 6 27.0 ± 5 .07
Left bundle branch 
block, n (%)
29 (94) 29 (94) .58
QRS duration, ms 165 ± 19 162 ± 18 .56
PR time, ms 193 ± 32 191 ± 29 .79
NYHA II, n (%) 11 (35) 11 (37) .93




17 (55) 20 (67) .35
Hypertension, n (%) 16 (52) 15 (50) .90
Diabetes, n (%) 5 (16) 9 (30) .20
Permanent atrial 
fibrillation, n (%)
4 (13) 6 (20) .46
Paroxysmal atrial 
fibrillation, n (%)
7 (23) 10 (33) .36
Smoker, n (%) 2 (6) 4 (13) .38
ACE inhibitors, n (%) 31 (100) 30 (100) 1.00
Betablockers, n (%) 29 (94) 30 (100) .16
Aldosterone 
inhibitors, n (%)
11 (35) 12 (40) .72
Diuretics, n (%) 17 (55) 19 (63) .51
CRT-D, n (%) 20 (65) 20 (67) .86
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calculated as an average of five consecutive cardiac cycles. The lat-
est contracting LV segments were identified for the anterior, lateral, 
and posterior LV segments. If the latest contraction of two of the 
LV segments was separated by ≤10 ms, the LV segment located 
between them was assigned the latest one. Based on this model, 5 
LV segments were defined; thus, the target LV segment for LV lead 
placement could be identified as the anterior, anterolateral, lateral, 
posterolateral, or posterior segment. The LV segments next to the 
target segment were classified as adjacent LV segments, and other 
segments were classified as remote LV segments.13
2.4 | Cardiac resynchronization therapy device 
implantation
The devices were implanted under local anesthesia. The right atrial 
(RA) lead was fixated in the appendage of the right atrium, and the 
right ventricular (RV) lead in the apex of the right ventricle. Occlusive 
contrast venography was performed in a 30-40° left anterior 
oblique (LAO) view and in a 30° right anterior oblique (RAO) view 
once the coronary sinus (CS) was cannulated. A selective venogram 
in a 30° RAO view was performed for the accurate measurement of 
the LV long-axis distance, which was divided into three equal seg-
ments: basal, middle, and apical (Figure 1). From the venogram in the 
LAO view, the left ventricle was divided into five equal segments 
(Figure 1) that corresponded to the five segmental divisions acquired 
in the preoperative ST-RS echocardiographic measurement. Thus, 
the target segment for the LV pacing lead was also located on the 
venogram in the LAO view. Substantial effort was made to achieve 
an LV lead position in a vein located in the target segment with the 
latest contraction. If there was no available vein in that segment, a 
vein located as close as possible was selected for lead placement.
The LV leads were delivered using the over-the-wire technique 
with standard coronary sinus cannulation catheters and a subselection 
catheter when required. As basal as possible of an LV long-axis posi-
tion for the stimulating electrode was preferred. The measurements 
of the pacing capture threshold (PCT) and the occurrence of phrenic 
nerve stimulation (PNS) were recorded. For the active fixation lead, a 
J-shaped stylet was inserted to press the helix toward the vessel wall. 
The lead was then fastened by clockwise rotation. The lead fixation 
was verified by pushing and pulling the lead during observation of lead 
movement using fluoroscopic imaging. If repositioning of the lead was 
needed, counterclockwise rotation was performed to free the lead 
helix from the vein wall. The R-wave, pacing impedance, and electri-
cal delays as well as the Q-LVsense, RVsense-LVsense, and RVpace-
LVsense were recorded from a pacemaker system analyzer (Model 
2090, Medtronic, Minneapolis. MN, USA) before removing the cathe-
ters. The leads were connected to a CRT-D or a CRT-P generator. The 
devices used were CRT defibrillators (CRT-D, Medtronic, Minneapolis, 
MN, USA) in 66% of the patients and CRT pacemakers (CRT-P, Abbot, 
Lake Bluff IL, USA) in 34% of the patients.
2.5 | Lead characteristics
The active fixation lead was a soft bipolar steroid-eluting lead (Attain 
Stability model 20066/4796, Medtronic Inc, Minneapolis, MN, 
USA). The lead body was 3.9 French (Fr) proximal and 3.4 Fr distal 
F I G U R E  1   Location and number of selected stimulating 
electrodes in different left ventricular segments in the active 
fixation lead group and in the quadripolar lead group
F I G U R E  2   Right anterior oblique fluoroscopic views of two 
patients with an active fixation bipolar lead (A + B) and passive 
fixation quadripolar lead (C + D). On the coronary sinus (CS) 
venograms (A + C) the arrows indicate the target veins in lateral 
side branches from CS. The target vein is located in the target 
left ventricular segment determined from speckle tracking 
echocardiography. B: The final lead placement of an active fixation 
bipolar lead. The helix (H) is fixated proximal in the vein. The 
proximal electrode (PE) is located in a basal third left ventricular 
long-axis position, and is used as the stimulating cathodal electrode. 
The distal electrode (DE) is in the mid third left ventricular long-axis 
segment. The high voltage right ventricular defibrillator lead (DL) 
is located close to the apex of the right ventricle. D: The final lead 
placement of a quadripolar lead. The distal end (LV1) is wedged 
into a small side branch. The proximal electrode (LV4) is used as 
the stimulating cathodal electrode
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(Figures 2 and 3). The electrode separation was 21 mm. Proximal to 
the ring electrode was a side screw. Longitudinal movements of the 
lead without torqueing did not engage the screw. The screw was also 
designed to elongate along the length of the lead body and to detach 
it from the vein wall when the traction force was increased to ap-
proximately 0.11 kilograms. The quadripolar leads (Figures 2 and 3), 
which were attained from the same vendor, had a diameter of 5.3 Fr 
proximal and 3.9 Fr distal. A dual bend lead, an S-shaped lead and a 
straight lead with tines were available. The dual bend lead was used 
in 19 patients (63%), the S-shaped lead in 10 of the patients (33%) 
and the straight lead in one patient (3%).
2.6 | Programming the device
Atrioventricular (AV) and interventricular adjustments were based 
on an automatic algorithm (adaptive CRT, Medtronic, Minnesota Inc, 
MN, USA) for patients with a CRT-D generator. The CRT-P devices 
were programmed without any LV off-set, and the sensed-AV-time 
was programmed to 120 ms The pacing modus was DDD, lower rate 
of 50 pulses per minute for those with no sinus node dysfunction. The 
active fixation bipolar leads were configured as bipolar, LV tip to RV-
coil/RV ring or LV ring to RV coil/RV ring. For the quadripolar leads, 
the preferred configuration was bipolar L3-L2, integrated bipolar LV1 
to the RV coil/RV ring, LV3 to the RV coil/RV ring, or LV4 to the RV 
coil/RV ring. A limited number of configurations for the quadripolar 
lead were selected for an accurate assessment of the location of the 
stimulating electrode in the LV long-axis view. The final LV lead posi-
tion was evaluated. The PCT, R-wave, and LV lead impedance were 
measured at the 2-, 6- and 12 month follow-up (FU) periods.
2.7 | Statistical analysis
Analyses were conducted according to the intention-to-treat con-
cept. Statistical analysis was performed by IBM SPSS Statistics for 
Windows, version 24.0 (IBM Corp., Armonk, NY, USA). Continuous 
variables are presented as the mean ± SD. Categorical variables are 
shown as frequencies and percentages. Differences were determined 
using Student's t-tests for continuous variables, the chi-square test 
for ordinal variables, or Fisher'exact test for categorical variables. We 
used histograms and Q-Q plots to evaluate the normality of the con-
tinuous variables. A P-value of < .05 was considered statistically signif-
icant. For sample size calculation, a 20% difference in the proportion 
of concordant LV lead placement, fluoroscopic distances, lead imped-
ance measurements, and PCTs were estimated. Descriptive data from 
a previous active fixation lead study (10) were used to predict values 
and standard deviations. Powered at 80%, with a two-sided alpha 
value of 0.05 to detect differences, about 60 patients were required 
for the different analyses. The study was not powered to compute sig-
nificant differences in infrequent events as lead dislocations.
3  | RESULTS
Initial successful implantation was obtained in 31 patients (100%) 
and 30 patients (97%) in the active fixation bipolar group and the 
quadripolar group, respectively. In 1 patient, the quadripolar lead 
dislodged repeatedly during implantation, and this could not be 
avoided by switching to the bipolar active fixation lead. Finally, an 
alternate thicker bipolar LV lead was implanted successfully. In three 
patients, LV lead dislodgement occurred, all in the active fixation 
group. For two of these three patients, the LV lead dislodged some 
hours after implantation, and the third instance of dislocation was 
recognized after 2 months. In all three patients, the same lead was 
repositioned successfully to the same coronary vein. We compared 
the size of target veins (Table 2). There was no difference in vein size 
at the active electrode or at the distal electrode. The average vein 
dimension at the proximal electrode was larger at the qauadripolar 
lead, corresponding with a more proximal position. During FU, there 
were no additional instances of reoperation, and there were no cases 
of device infection. All patients were alive the 12 month FU. Table 2 
summarizes the characteristics of the 62 implantation procedures. 
The locations of the targeted LV segments were anterior (10%), an-
terolateral (11%), lateral (44%), posterolateral (30%), and posterior 
(5%). The distribution of the locations of the selected stimulating 
electrodes for each LV lead is shown in Figure 1. The target LV lead 
placement, which was defined as a position in a concordant or adja-
cent LV segment, was achieved in the majority of the patients with 
no statistically significant differences between the patient groups 
(Table 3). For both LV lead groups, the selected active electrodes 
were stimulating the LV from a position close to the distal part of the 
basal segments in majority of the patients. The proximal electrode of 
the quadripolar LV lead was closer to the CS than that of the active 
fixation LV lead. However, there was no statistically significant dif-
ference between the active fixation group and the quadripolar group 
concerning the proximity of the stimulating electrode to the coro-
nary sinus, neither in absolute values nor in distance as a percentage 
of the distance from the CS to the apex.
F I G U R E  3   A, The bipolar lead with distal angled shape has an 
exposed side screw for fixation located 15 mm proximal to the 
proximal electrode. The electrode separation is 21.0 mm. The 
maximum lead body diameter is 3.9 Fr. B, Demonstrates a close 
range view of the exposed side screw. C, The quadripolar leads: An 
S-shaped lead, a straight lead with tines and a dual bend lead. The 
distances between the electrodes are 21 mm (LV1-LV2), 1.3 mm 
(LV2-LV3), and 21 mm (LV3-LV4). The maximum lead body diameter is 
5.3 Fr A + B: Photo by the author. C: Photo from the manufacturer
(A)
(B)
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The electrical performance was recorded at implantation and at 
the 2-, 6- and 12 month FU periods (Table 4). For the final selected 
pacing configurations, the mean PCT for the active fixation lead was 
higher at implantation but was not significantly different at FU. A 
PCT < 2.5 V/0.4 ms at implantation was achieved in 100% of patients 
in both groups. At the 12 month FU, a PCT < 2.5 V/0.4 ms was re-
corded for 93% of patients in both groups. The PCT for the proximal 
electrode was significantly higher for the quadripolar lead than for the 
active fixation lead (2.83 V vs 1.31 V; P = .003). For the quadripolar 
lead, the PCT at the proximal electrode was ≥ 3.5 V for 10 patients 
(33%); however, for the active fixation lead, the PCT was ≥ 3.5 V only 




(n = 30) P-value
Number of veins attempted, 
n
1.1 ± 0.52 1.29 ± 0.40 .26
Number of fixation attempts, 
n
1.7 ± 1.5 Not relevant
Total LV lead implantation 
time, min
13.2 ± 11 12.2 ± 12 .75
Total procedure time, min 77 ± 22 76 ± 21 .82
Fluoroscopy time, min 15 ± 7 15 ± 10 .68
Fluoroscopy doses, mGY 
(mGym2)
329 ± 236 
(3.0 ± 2.1)
319 ± 426 (3.2 ± 4.3) .91 (0.85)
Note: Total LV lead implantation time was measured from the start of LV lead insertion and 
included advancement of the lead to the target site, fixation attempts, repositioning to other 
locations, electrophysiological measurements, and removal of supporting catheters.
TA B L E  2   Characteristics of the 
implantation procedures
TA B L E  3   Left ventricular lead positions
Active fixated 
lead (n = 31)
Quadripolar 
lead (n = 30)
P 
value
Lead in the 
concordant segment, 
n (%)
12 (39) 19 (63) .06
Lead in an adjacent 
segment, n (%)
15 (48) 6 (20) .02
Lead in a concordant 
or adjacent segment, 
n (%)
27 (87) 25 (83) .69
Lead in a remote 
segment n (%)
4 (13) 5 (17) .69
Distance from CS to 
proximal electrode, 
mm
32 ± 10 19 ± 15 .00
Distance from CS to 
distal electrode, mm
51 ± 9 53 ± 13 .51
Distance from CS to 
active electrode, mm
38 ± 10 35 ± 13 .36
Distance from CS 
to active electrode 
as percentage of 
distance from CS to 
apex, %
36 ± 11 33 ± 12 .26
Vein size at proximal 
electrode, Fr
8.1 ± 3.0 10.8 ± 6.2 .04
Vein size at distal 
electrode, Fr
6.2 ± 2.7 5.3 ± 2.3 .20
Vein size at active 
electrode, Fr
7.3 ± 2.9 8.3 ± 3.2 .20
Abbreviation: CS, coronary sinus.











1.09 ± 0.48 0.77 ± 0.25 .02
PCT at the 2 month 
FU, V@0.4 ms
1.23 ± 0.77 1.00 ± 0.62 .21
PCT at the 6 month 
FU, V@0.4 ms
1.16 ± 0.76 1.02 ± 0.74 .46
PCT at the 
12 month FU, 
V@0.4 ms
1.23 ± 0.75 1.03 ± 0.86 .35
LV lead impedance 
at implantation, 
Ohm
539 ± 159 414 ± 94 .00
LV lead impedance 
at 6 months
561 ± 156 443 ± 96 .01
LV lead impedance 
at 12 months
545 ± 142 433 ± 97 .04
R wave, mV 17 ± 8 13 ± 8 .03
Q-LV sense, ms 155 ± 30 154 ± 35 .88
RVsense- LVsense, 
ms
101 ± 26 97 ± 36 .67
RVpace- LVsense, 
ms
142 ± 27 143 ± 31 .94
Abbreviations: PCT, pacing capture threshold; FU, follow-up; LV, left 
ventricle; RV, right ventricle; Q-LV sense, interval from QRS onset to 
first peak of the LV electrogram.
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at one time or another after discharge from the hospital experienced 
some kind of discomfort from PNS. Six of those patients (19%) were 
in the active fixation group, and three (10%) were in the quadripolar 
group. In all cases, the PNS was resolved by reprogramming the device.
4  | DISCUSSION
Implanters of CRT devices are concerned about the acute and chronic 
lead stability. Much effort has been devoted to developing leads that 
provide stability and a low PCT, but that have preserved trackability 
along tortuous veins. LV leads have evolved from unipolar to bipo-
lar and, further, to quadripolar models. Compared to bipolar leads, 
quadripolar leads provide more available pacing vectors and less 
PNS. Quadripolar leads have been associated with better clinical re-
sponse and lower mortality, based on retrospective analyses.9,14 In 
these trials, the LV leads were placed empirical and not targeted, and 
the final LV lead positions were not assessed. Consequently, it is not 
possible to conclude if the clinical superiority of quadripolar lead is 
a consequence of being quadripolar with multiple options for pacing 
configurations, or if it is because of implantation issues and the final 
position of the active electrode. According to the subgroup analyses 
of randomized trials, such as MADIT-CRT and REVERSE, LV pacing 
from an apical site is associated with less favorable outcomes and 
high PNS.4,15 However, operators may be tempted to sacrifice a non-
apical position to achieve a stable position and low PCT by wedging 
the lead in a small apical branch. The optimal long-axis LV lead posi-
tion is debatable, and the future may show that the optimal long axis 
position occurs on an individual basis. A nonrandomized multicenter 
trial that compared active fixation LV leads with quadripolar LV leads 
reported noninferior clinical outcomes for the active fixation leads.16 
Our trial is the only randomized clinical trial comparing active fixa-
tion LV leads with quadripolar LV leads. At implantation, the PCT 
was lower in the quadripolar group than in the active fixation group, 
but the difference decreased later, and there were no significant dif-
ferences at the 6- and 12 month FUs. The pacing impedance was 
significantly higher (approximately 20%) in the active fixation group 
than in the quadripolar group and may lead to a moderate increase 
in battery longevity compared to devices with quadripolar LV leads.
Our hypothesis was that in large veins, an active fixation bipolar 
LV lead will enable a more proximal position of the stimulating elec-
trode compared to a quadripolar lead. We aimed to achieve a position 
of the stimulating LV lead electrode as far from the apex as possible. 
Nevertheless, we did not find any significant difference between 
the two types of LV leads concerning the proximity of the ultimately 
selected stimulating electrode to the coronary sinus. Thus, the active 
fixation lead did not promote a more basal placement of the stimu-
lating electrode. An explanation for this may be that in many cases of 
quadripolar leads, it was possible to wedge the lead tip in an early side 
branch to stabilize the stimulation electrode in a basal LV segment. 
Furthermore, the electrically inactive helix of the active fixation bipo-
lar lead was placed proximal to the proximal electrode, thus prohibiting 
placement of the proximal electrodes in the vein close to the coronary 
sinus. The PCT for the proximal electrode was significantly higher for 
the quadripolar lead than for the active fixation lead (2.84 vs 1.42 V). 
This may be because of the lower amount of pressure toward the wall 
for the passive leads than for the active fixation leads in the proximal 
vein segment. On the contrary, the PCTs for the distal electrodes were 
lower for the quadripolar leads at implantation. An explanation for this 
may be that the S-shape or dual bend shape and the larger body diame-
ter of the quadripolar lead may cause more tension toward the vein wall 
than that of the distal end of the active fixation lead. Quadripolar leads 
with active fixation were not available when the current trial was per-
formed, but later, a quadripolar active fixation lead with a similar helix 
for fixation was approved (Medtronic lead model 4798). In this quad-
ripolar version, the fixation mechanism is located between electrodes 3 
and 4, which may potentially improve the lead stability and reduce the 
PCT for the most proximal electrodes, even in large coronary veins. The 
LV lead dislodgement rate is low in recent trials with quadripolar leads, 
and in the Performa Trial, a dislodgement rate of 1.4% was reported.17 
In the current trial, which was not powered to show differences in the 
rate of lead dislodgement, there were no dislodgements of the quad-
ripolar leads; however, in the active fixation group, two postoperative 
dislodgments and one late dislodgment occurred. These three patients 
were retrospectively evaluated. One patient had a large-diameter coro-
nary vein (16.5 Fr at the point of helix fixation) and needed four fixation 
attempts at the primary operation. The other 2 patients with LV lead 
dislodgement showed no unusual vein-anatomy and only one fixation 
attempt was needed initially. The present trial did not prove that adding 
an active fixation mechanism to bipolar lead makes them more stable 
than passive fixation quadripolar leads. The new location of the fixation 
helix between electrodes 3 and 4 in the Medtronic lead model 4798 may 
potentially further augment the stability of the active fixation lead.18 
There is an obvious concern about the extractability of active fixation 
LV lead. Unlike the leads with side lobes of the lead, the Attain Stability 
is fixated with a side helix constructed to uncoil in response to retractive 
force. However, the data on extraction safety are limited and this must 
be taken into account when choosing an LV lead.
In this randomized trial, comparing an active fixation bipolar lead 
and quadripolar passive fixation leads, no important differences in 
implantation variables or long-term electrical performance were 
found. Furthermore, there were no differences in the ability to 
reach a proximal concordant or adjacent LV segment for targeted 
LV stimulation.
4.1 | Study limitations
The study was a single-center study with a relatively small sample 
size. Therefore, the extension of the validity of these results to 
other centers and implanters is not possible. The clinical findings, as 
changes in NYHA classification or echocardiographic response, were 
not compared in the present study.
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